# 35 Year Old female with bilateral neck mass

Milad AbusagFellow section Endocrinology Diabetes and Metabolism2/27/2014

# HPI

- $\vee$  35 year old F with PMH of HTN, asthma.
- $\vee$  Was in her usual state of health until 2 years ago
- v c/o intermittent palpitation + Wt loss à blood drawn à abnormal TFT
- ✓ Abnormal exam à US thyroid showed large bilateral neck mass not associated with her thyroid
- ✓ No h/o voice change, neck pain, difficulty swallowing, increase in sweating, headache or change in her periods.

PMH: ÜMild intermittent asthma **ÜHTN** ÜAnxiety Family History: Ü No FH of thyroid cancer Ü No FH of neck tumor Surgical history: ÜNone Social history ÜNever smoke, no alcohol, no illicit drugs.

Home medications ÜAlbuterol PRN ÜDiltiazem 240 mg po daily ÜClonazepam PRN (anxiety)



# ROS

**Constitutional:** Wt loss (40 pounds over 2 years) **HENT:** No blurred vision, no double vision, no sore throat, no headache. **Neck:** + neck mass, no neck pain **Cardio/pulm:** No CP, + intermittent palpitation, no orthopnea or **PND GI:** No N/V/D, no constipation, no melena or hematochezia **GU:** Negative, normal menses **Skin/MSK:** negative, no rash **Neuro** negative

### **On examination**

Vitals: BP 134/94, Pulse 88, no fever, RR 14, BMI 21

General: awake alert, comfortable

**HEENT:** normocephalic non traumatic, no pallor, no jaundice. No double vision, no increase insertion, no exophthalmos

**Neck:** supple, no thyromegaly, small bilateral pulsatile, non tender masses in the upper part of the neck.

**CVS/Pulm:** clear equal air entry no added sounds, regular pulse, S1 + S2, no murmur.

Abd: soft lax, no organomegaly, no tenderness, audible bowel sounds.

Skin: normal, not diaphoretic

Lymphatic: No cervical, axillary or inguinal Lymphadenopathy

Neuro: alert, no tremor, CN intact, DTR normal

**Psych:** normal mood, and affect

#### **Radiology ((outside facility))**

#### CT scan neck



- a) Enhancing masses at the level of the carotid bifurcations.
- b) The right mass measures 3.2 x 2.6 x 5.3 cm, Lt mass 2.7 x 1.7 x 4.4 cm

# **Differential Diagnosis**

- 1. Carotid artery
- Aneurysm
- Pseudo aneurysm
- Dissection
- 2. Jugular Vein
- Thrombosis
- Thrombophlebitis
- 3. Inflammatory
- Abscess
- 4. Lymph nodes
- Metastaic LN
- Lymphoma
- 5. CN ((X, XI, XII, sympathetic chain))
- Paraganglioma
- Neuroblastoma



# **General labs**

Test/date	11/2013	-
Na/K	138/3.7	
BUN/Cr	6/0.8	
eGFR	84	
ALP	83	
ALT/AST	9/12	
Hb	11.6	
WBC	7.6	
Plt	322	

## **Endocrine work up**

Test/date	2/12	6/12	9/12	12/12	2/13	5/13	8/13	11/13	
TSH (0.4 – 4.5)	6.59	6.27	4.157	0.41	0.16	3.46	6.32	2.45	
FT4 (0.8 – 1.8)		0.85	1.06		1.06	0.89	0.74	1.06	
T3 (20 – 195)						106		97	
FT3 (0.6 – 1.8)	1.27	2.18	1.81						
TPO Ab					20				
Tg Ab					640				
TSI					<1.0				
Test/da	te		10/2012	لاب	2/2013		11/2	)13	
Catecholamines tin NE (ref: 15 - 80 mcg/24h E (ref: 0 - 20 mcg/24hrs) Dopamine (ref: 65 – 400	ned urine nrs)	D	IC	CI	<i>NE 94</i> E 9.0	Ē			
	mcg/24hrs)				D 320				
Plasma Metanephr Normetanephrines (< 0. Metanephrines (< 0.5)	mcg/24hrs) ines .9)				D 320 NM 1.5 M 0.3		NM 0 M <0	).58 ).2	
Plasma MetanephrNormetanephrines (< 0.4)	mcg/24hrs) ines .9) 8.0)		3.0		D 320 <i>NM 1.5</i> M 0.3 5.2		NM 0 M <0	).58 ).2	





**T1 MRI:** Enhancing masses, the right mass measures 3.2 x 2.6 x 5.3 cm, Lt mass 2.7 x 1.7 x 4.4 cm.



- a) Bilateral internal and external arteries are splayed by bilateral tumors.
- b) Despite encasement by the tumors, both internal and external carotid arteries demonstrate normal caliber without convincing irregularity or narrowing





- a) Normal physiologic radiotracer distribution is seen in e salivary glands, myocardium, liver, bowel and bladder
- b) Asymmetrically increased activity in the right suprarenal region raises the question of a pheochromocytoma



# **MRI/CT abdomen & pelvis**

#### **Ü MRI adrenal glands**

• No significant abnormality noted, no focal nodularity or mass lesion is identified. No evident lesion to correlate with the abnormal MIBG scan.

#### ü CT abdomen

• No evidence for adrenal mass or peri-aortic paraganglioma





#### **Underwent surgical resection of both masses**

#### **Pathology report:**

Paraganglioma (5.1 cm) in Rt carotid bifurcation Paraganglioma (3.5 cm) in Lt carotid bifurcation

#### **Genetic testing Deleterious mutation** was detected in the **SDHD** gene



# **Clinical Qs**

• What is the prevalence of pheochromocytomas in patient with SDHD-associated head-and-neck paragangliomas?

• How common is SDHD-associated head-and-neck paragangliomas (HNP) with negative FH?

# Few lines on PG

- Is a rare neuroendocrine tumor
- Accounts for 0.012% of all human tumors and 0.6 % of a 1 H&N neoplasm.
- o 75% of PG are sporadic and 25% are hereditary
- H&N PG commonly originate from paraganglion cells in carotid body, vagal nerve, middle ear, and Jugular foramen (Glomus tumor)
- 80% of these are either carotid body or Jugular area.

#### **SDH Complex II**



- SDH complex is located on the inner membrane of the mitochondria and participates in both the *Citric Acid Cycle and electron transfer chain*
- $\emptyset$  SDHA converts succinate to fumarate. This reaction also converts FAD to FADH<sub>2</sub>.
- $\oslash$  Electrons from the FADH<sub>2</sub> are transferred to the SDHB
- Ø Hereditary paraganglioma syndrome is due to mutations in one of three genes: SDHB, SDHC, SDHD (succinate dehydrogenase subunit B, C, or D)



## **Few words on SDH mutations**

- ✓ SDH mutations are inherited in a dominant manner.
- ✓ This means that there is a 50% chance that the offspring of an individual with a SDH mutation will inherit the disease. Men and women are equally likely to inherit it.
- The exception to this inheritance pattern is SDHD gene mutations, which are still inherited in a dominant manner, but individuals only develop tumors <u>if</u> <u>the gene mutation is inherited from their father</u>.

Pheochromocytomas and extra-adrenal Paragangliomas detected in screening patients with SDHD head-and-neck Paragangliomas.

B Havekes<sup>1</sup>, A A van der Klaauw<sup>1</sup>, M M Weiss<sup>2</sup>, J C Jansen<sup>3</sup>, A G L van der Mey<sup>3</sup>, A H J T Vriends<sup>2</sup>, B A Bonsing<sup>4</sup>, J A Romijn<sup>1</sup> and E P M Corssmit<sup>1</sup>

<sup>1</sup>Department of Endocrinology and Metabolic Diseases, <sup>2</sup>Center of Human and Clinical Genetics, <sup>3</sup>Department of Otorhinolaryngology and <sup>4</sup>Department of Surgery, Leiden University Medical Cente PO Box 9600, 2300 RC Leiden, The Netherlands

- Ø Data reviewed of all consecutive HNP patients who visited the outpatient clinic at the Department of Endocrinology since 1988
- Ø 154 pts with HNPG
- Ø 93 patients with SDHD associated HNP included in the study.
- Screening consisted of measurement of 24 h urinary excretion of catecholamines and/or their metabolites.
- Ø In patients, in whom urinary excretion was above the reference limit, imaging studies with MIBG and MRI and/or CT were performed.
- Ø Median follow-up was 4.5 years (range 0.5–19.5 years)

No.	Sex, age (years) <sup>a</sup>	HTN	Start screening	Dx	FH of PG	
1	M, 64	Yes	1997	2004	Positive	
2	M, 35	No	2001	2001	Positive	
3	F, 40	Yes	1998	2005	Positive	
4	M, 61	Yes	2006	2006	Positive	
5	M, 60	Yes	2002	2006	Positive	
6	F, 62°	Yes	1988	2002	Positive	
7	M, 24	Yes	1988	1988	Positive	
8	F, 48	Yes	1988	1988 <sup>e</sup>	Negative	
9	M, 30	Yes	1990	1990	Positive	
10	M, 33	Yes	2004	2005	Positive	
11	M, 35	Yes	2004	<b>2006</b> <sup>d</sup>	Positive	
12	F, 43	No	2002	2003	Positive	
13	M, 32	No	2007	2007	Positive	
14	M, 34	yes	2003	2004	Positive	
15	M, 40	No	2007	2007	Negative	
16	M, 61	No	2002	2004	Positive	
17	M, 64 <sup>c</sup>	Yes	1998	2006	Negative	
18	F, 42 <sup>c</sup>	No	2005	2006	Positive	
19	M, 43	No	2003	2006	Positive	
20	F, 67°	Yes	2005	2005 2005		
21	M, 40	Yes	2003	2005	Negative	
22	M, 45	Yes	2004	2006	Positive	
23	M, 25	Yes	1989	2004	Positive	
24	F, 35	No	2002	2005	Positive	
25	F, 49	No	2000	2003	Positive	
26	F, 64	Yes	2003	2007	Negative	
27	M, 34	No	2005	2006	Positive	
-28-	M, 47	No	2005	2006	Positive	

Endocrine-Related Cancer (2009) 16 527–536



# Results

- ü 28 out of 93 patient with HNP found to have elevated catecholamines (30%)
- Ü Intra-adrenal paragangliomas (pheochromocytomas) were identified in 11 out of 28 pts (39%)
- Ü Extra-adrenal paragangliomas in *abdomen or pelvis* were found 6 patients (21%)
- **Ü** Mediastinal paragangliomas found in 2 pts (7%)
- U In 8 patients with HNP and increased catecholamine and/or catecholamine metabolite excretion, *No* pheochromocytomas or extra-adrenal Paraganglioma identified (28%).
- Uptake of MIBG in the glomus tumor was found in seven out of these 8 patients
- **ü** 2% of **SDHD** associated HNP have negative FH of PG

# Summary

oIndividuals with an *inherited form of paragangliomas* have an increased risk to develop *paragangliomas or pheochromocytomas* over their lifetime (around 30%)

oHereditary paraganglioma syndrome is due to mutations n one of three genes:
SDHB, SDHC, SDHD (succinate dehydrogenase subunit B, C, or D)
oCollectively, SDH mutations are found in 1-10% of apparently sporadic
Paraganglioma and 20-30% of seemingly inherited Paraganglioma
oIndividuals with mutations in the SDHD gene seem to develop more head and neck tumors. These tumors are more likely to be multifocal
oThere seems to be an earlier age of onset for individu with a mutation in the SDHD gene, with approximately 73% manifesting the disease by age 40.
oIndividuals with mutations in the SDHB gene seem to have more extra-adrenal abdominal tumors than those with mutations in the SDHD gene
oApproximately 45% of individuals with mutations in the SDHB gene will display the disease by age 40.



### **NANETS Recommendations:**

• Individuals with hereditary paraganglioma syndrome should have regular screening for signs of paraganglioma development, beginning at age 10.

#### **Screening guidelines**

- **1.** Annual history and physical examination, including blood pressure measurements
- 2. Biochemical analysis every 6-12 months (urine catecholamines, plasma metanephrines)
- CT/MRI Imaging (every other year) *SDHD/SDHC*: Head/neck *SDHB*: Abdomen, thorax, pelvis
- 4. I-MIBG imaging and/or full-body MRI (every four years)



# **Back to my patient**

Ü After the surgery >> sever orthostatic hypotension ((currently managed with compression stocking + salt tab))
Ü Repeated plasma M&NM were normal
Ü Future Plan:
∨ Biochemical analysis every 6-12 months (urine catecholamines, plasma metanephrines)
∨ Radiological studies (every other year)

### References

- Glenner GG and Grimley PM. Tumors of the Extra-Adrenal Paraganglion System. Bethesda, MD: Armed Forces Institute of Pathology, 1974
- Lustrin ES et al: Radiographic evaluation and assessment of paragangliomas.
   Otolaryngologic Clinics of N. America 34(5) Oct 2001
- Som PM, Bergeron RT. Head and Neck Imaging. St. Louis: Mosby Year Book, 1991.
   Raofi B, Kumar A, Muscato C. Glomus faciale, glomus jugulare, glomus tympanicum, glomus vagale, carotid body tumors and simulating lesion. Radiologic Clinics of North America 38(5) Sept 2000
- Novelline RA, Squire LF. Living Anatomy. Philadelphia: Hanley & Belfus, Inc., 1987

# Thank you Milad Abusag MD 02/27/2014

